WHO Raises Concern Over Critical Scarcity of Weight-Loss Jabs

Fewer than one in 10 individuals that would benefit from GLP-1 drugs like Wegovy are able to get them, caution the WHO as it releases its inaugural advice on the therapies.

Given over a billion individuals worldwide now classified as obese, it is calling for increased and just access to these injectable treatments.

According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.

"The new guidelines recognises that excess weight is a lifelong illness that can be addressed with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and logistical bottlenecks are key hurdles to universal access to the injections that can aid individuals in losing considerable weight, notes the agency.

Weight-Loss Drug Scarcity

Despite the present most favorable outlook, the manufacturing of such drugs could only cover approximately 100 million people – fewer than 10% of those who need them, as stated by the health organization.

The recommendation calls on governments and firms to expand availability, via measures including voluntary licensing.

Exclusive production rights on a key compound – the main component of the drug Wegovy – is due to expire in a number of countries in 2026.

The Way Weight-Loss Jabs Function

GLP-1 drugs mimick a biological compound to slow digestion, reduce hunger and enhance satiety so individuals consume fewer calories.

Individuals commonly start to lose weight in the initial weeks of commencing the regular doses.

Studies indicates patients may see weight return after a year of discontinuing the medication, because their usual appetite come back.

Being carrying excess weight increases your risk for contracting diseases, such as type 2 diabetes, heart disease, stroke, and certain cancers.

Excess weight impacts people in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.